# A Phase 3 Randomized Parallel Group Study Comparing the Efficacy & Safety of SB206 & Vehicle Gel in the Treatment of MC (B-SIMPLE1)

> **NCT03927716** · PHASE3 · COMPLETED · sponsor: **Novan, Inc.** · enrollment: 352 (actual)

## Conditions studied

- Molluscum Contagiosum

## Interventions

- **DRUG:** SB206 12%
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03927716
- **Lead sponsor:** Novan, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-03
- **Primary completion:** 2019-10-28
- **Final completion:** 2020-01-29
- **Target enrollment:** 352 (ACTUAL)
- **Last updated:** 2022-12-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03927716

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03927716, "A Phase 3 Randomized Parallel Group Study Comparing the Efficacy & Safety of SB206 & Vehicle Gel in the Treatment of MC (B-SIMPLE1)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03927716. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*